Author/Authors :
Larki ، Pegah - Shahid Beheshti University of Medical Sciences , Gharib ، Ehsan - Shahid Beheshti University of Medical Sciences , Yaghoob Taleghani ، Mohammad - Shahid Beheshti University of Medical Sciences , Khorshidi ، Fatemeh - Shahid Beheshti University of Medical Sciences , Nazemalhosseini-Mojarad ، Ehsan - Shahid Beheshti University of Medical Sciences , Asadzadeh Aghdaei ، Hamid - Shahid Beheshti University of Medical Sciences
Abstract :
The detection of KRAS and BRAF mutations is a crucial step for the correct therapeutic approach and predicting the epidermal growth factor receptor (EGFR)-targeted therapy resistance of colorectal carcinomas. The concomitant KRAS and BRAF mutations occur rarely in the colorectal cancers (CRCs) with the prevalence of less than 0.001% of the cas¬es. In patients with KRAS-mutant tumors, BRAF mutations should not regularly be tested unless the patient is participating in a clinical trial enriching for the presence of KRAS or BRAF-mutated tumor. The current report demonstrates a case with advanced adenocarcinoma of the colon showing the coexistence of KRAS and BRAF mutations and may have profound clinical implications for disease progression and therapeutic responses.
